Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021
Baird Maintains Outperform on Allbirds, Lowers Price Target to $7
Baird analyst Mark Altschwager maintains Allbirds (NASDAQ:BIRD) with a Outperform and lowers the price target from $8 to $7.